Theradiag, a French company that specializes in in vitro diagnostics and theranostics, has entered into a partnership agreement with Biogen to provide its Lisa Tracker kits to monitor patients treated with Biogen’s infliximab biosimilar Flixabi, which was approved in Europe in 2016.
Theradiag, a French company that specializes in in vitro diagnostics and theranostics (targeted therapy based on targeted diagnostic tests), has entered into a partnership agreement with Biogen to provide its Lisa Tracker kits to monitor patients treated with Biogen’s infliximab biosimilar Flixabi, which was approved in Europe in 2016.
The partnership will allow Biogen to supply Lisa Tracker monitoring kits in France and other European countries to optimize the treatment of patients receiving the biosimilar. Flixabi is indicated for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriasis, and psoriatic arthritis. Under the agreement, Theradiag will be Biogen’s preferred supplier of infliximab monitoring kits. Theradiag will also handle implementation, provide training to laboratories in how to use the kits, and follow up on clinician requests concerning monitoring.
Lisa Tracker kits are used to monitor patients taking biotherapies for diseases ranging from gastroenterology, rheumatology, and dermatology to oncology. The kits allow clinicians to simultaneously monitor patients’ trough plasma levels of 3 parameters within 3 hours of reaction from a serum sample in order to anticipate, optimize, and better manage patients’ treatment with infliximab:
Consensus statements support therapeutic drug monitoring (TDM) used to guide and optimize anti-TNF therapy in IBD, particularly in situations of treatment failure. One such statement, issued by the Australian Inflammatory Bowel Disease Consensus Working Group and other international experts, recommended TDM of anti-TNF agents upon treatment failure, following successful treatment induction, and when contemplating a drug holiday.
However, the group said there is inconsistent evidence for proactive TDM, and therefore advised that TDM should be performed for patients in stable remission only if results are likely to impact clinical management.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.